Contact Us Today!


or Use Our Simple Online Form to Give Us Feedback

We welcome your comments and feedback. Please include contact information if you'd like a response.

Did you find this page helpful?

If you would like a response, please include your contact information.

D. Bradley Welling, M.D., Ph.D., FACS

Chief of Otolaryngology, Massachusetts Eye and Ear
Chief of Otolaryngology, Massachusetts General Hospital
Walter Augustus LeCompte Professor and Chair of Otology and Laryngology, Harvard Medical School
Specialties: Otology and Neurotology
Vestibular/Balance Disorders
Phone Number: 617-573-3632
Fax: 617-573-3415
Location: 243 Charles Street
Boston, MA 02114
Office Hours: Check with office.
Board Certification: Otolaryngology-Head and Neck Surgery
Graduate School Pathobiology, The Ohio State University
MD University of Utah
Internship University of Iowa Hospitals and Clinics
Residency University of Iowa Hospitals and Clinics
Fellowship Otology, Neurotology and Skull Base Surgery, The Ear Foundation, Vanderbilt University
Teaching Affiliation Walter Augustus LeCompte Professor and Chair of Otology and Laryngology, Harvard Medical School
Biographical Profile:

Clinical Interests

Dr. Welling's clinical interests involve caring for patients with diseases of the ear and lateral cranial base. More specifically, he focuses on hearing loss, cochlear implants, auditory brainstem implants, as well as facial paralysis and deafness related to Neurofibromatosis type 2 (NF2)-associated tumors.

Research Interests
Dr. Welling's research efforts primarily focus on NF2-associated vestibular schwannomas.

Select Publications
Acoustic neuroma: a cost-effective approach. Welling DB,  Glasscock ME, Woods CI, Jackson CG. Otolaryngol HNSurg 1990:103(3):364-370. 

Mutational spectrum in the neurofibromatosis type 2 gene in sporadic and familial schwannomas. Welling DB, Guida M, Goll F, Pearl DK, Glasscock ME, Pappas DG, Linthicum FH, Rogers D, Prior TW. Hum Genet 1996:98(2): 189-93. 

Clinical manifestions of mutations in the neurofibromatosis type 2 gene in vestibular schwannomas. Welling DB. Laryngoscope 1998: 108(2):178-89.

Analysis of the human neurofibromatosis type 2 gene promoter and its expression. Welling DB, Akhmametyeva EM, Daniels RL, Zhu L, Miles-Markley BA, Chang L-S. Otolaryngol HN Surg 2000; 123:  413-418. 

cDNA microarray analysis of vestibular schwannomas. Welling DB, Lasak JM, Akhmametyeva EM, Gaheri B, Chang L-S. Otol Neurotol 2002;23(5): 736-748.

Cochlear implantation in the neurofibromatosis type 2 patient: long-term follow-up. Neff BA, Wiet RM, Lasak JM, Ramsden R, Cohen N, Welling DB. Laryngoscope 2007;117:1069-1072.

AR42, A Novel Histone Deacetylase Inhibitor, as a Potential Therapy for Vestibular Schwannomas and Meningiomas. Bush ML, Oblinger J, Brendel, V, Santarelli G, Huang J,  Akhmametyeva EM,  Burns SS,  Wheeler J, Davis J,  Chaudhury AR, Kulp S, Chen C-S, Yates C, Chang L-S, Welling DB,  Jacob A. Neuro-Oncol 2011; 13:983-989, 2011. PMID: 21778190. 

Preclinical Validation of AR42, a Novel Histone Deacetylase Inhibitor, as Treatment for Vestibular Schwannomas. Jacob A, Oblinger J, Bush ML, Brendel V, Santarelli G, Chaudhury AR, Kulp S, La Perle K, Chen C-S, Chang L-S, Welling DB. Laryngoscope 2012;122(1):174-189.

Virtual temporal bone dissection system: OSU virtual temporal bone system:  development and testing. Wiet GJ, Stredney D, Kerwin T, Hittle B, Fernandez SA, Abdel-Rasoul M, Welling DB. Laryngoscope 2012; Mar; 122, suppl 1:S1-12.  Epub 2012, January 31. 

Histone deacetylase inhibitor AR-42 differentially affects cell-cycle transit in meningeal and meningioma cells, potently inhibiting NF2-deficient meningioma growth. Burns SS, Akhmametyeva EM, Oblinger JL, Bush ML, Huang J, Senner V, Chen CS, Jacob A, Welling DB, Chang LS. Cancer Res 2013 Jan 15;73(2):792-803.

A complete list of research publications can be seen at